As oncology social workers, you already understand something medicine is only beginning to quantify: a cancer diagnosis doesn’t just impact the body. It can fracture identity, dissolve a sense of the future, and leave patients grappling with questions no medication has ever truly answered. “What does my life mean now? How do I face what’s coming?” For decades we’ve held space for those questions with presence and skill, often with the quiet frustration that our tools could only go so far, but that may be changing.
An Emerging Treatment Landscape
Psilocybin-assisted therapy is a structured treatment that pairs a carefully dosed psychedelic compound with professional therapeutic support. It’s generating some of the most compelling data in psychosocial oncology in a generation. Since 2011, more than 10 clinical trials have evaluated psilocybin for depression, anxiety, and existential distress in cancer patients, with most studies demonstrating safety and feasibility, even during active chemotherapy. In a landmark study, 80% of participants showed a sustained treatment response, and 70% rated their psilocybin experience among the most personally meaningful of their lives. These aren’t just symptom scores. They’re people rediscovering connection, meaning, and peace in the face of life-threatening illness.
A Personal Path into This Work
I came to this work through my own experience with death anxiety and existential distress, where psilocybin offered something conventional approaches never had: a genuine shift in how I related to my own mortality. That led me to train as a facilitator, and today I accompany patients and families through preparation, dosing, and integration. I share this not to center myself, but because it matters for our profession to hear: this is not fringe work. It is the most meaningful clinical work I have done.
Legal Access Is Already Here
Psilocybin sessions are no longer a distant possibility for many patients. Oregon became the first state to legalize supervised psilocybin use under Measure 109 (in 2020), allowing adults 21 and over to access it at licensed service centers without a medical diagnosis or referral. Colorado followed with Proposition 122 (in 2022) and launched licensed healing centers in 2024. Both states use a preparation-dosing-integration model guided by trained facilitators.
Access and affordability remain real barriers. Sessions typically run $1,000–$3,500 and aren’t covered by insurance, but these frameworks are the first legal pathway for patients outside clinical trials.
The Psychosocial Core of the Treatment
What’s often overlooked is that this therapy is, at its heart, a psychosocial intervention. The medicine is only one element; the preparation and integration sessions surrounding it are increasingly seen as central to its therapeutic mechanism. This is deeply familiar territory: building therapeutic alliance, facilitating meaning-making, supporting anticipatory loss, navigating family systems. We already know how to do this work, we just need to learn the new landscape it’s being done in.
How to Talk with Patients and When to Refer
Start by learning to recognize candidates: patients with anxiety, depression, or existential distress resistant to conventional treatment, who are medically stable and screened for contraindications like a history of psychosis. A simple opener: “There are some newer approaches to the kind of distress you’re describing-would you be open to hearing about them?”
From there, connect patients to licensed centers through Oregon’s provider directory (oregon.gov/oha) or Colorado’s Natural Medicine Division (dora.colorado.gov). You don’t need to be a facilitator yourself to play a vital role. Knowing the landscape and walking alongside a patient through the referral is squarely within your scope.
Your Role in What’s Ahead
Researchers increasingly call for integrating psychedelic-assisted therapy alongside conventional palliative and psycho-oncological care, not as an alternative, but as an enhancement of holistic healing. Oncology social workers are well-positioned to contribute as trial therapists, facilitators, educators, and the professionals who help patients make sense of these experiences. The field is moving quickly. Now is the time to engage, to raise our voices in clinical and policy spaces, and to bring our irreplaceable perspective to a treatment that demands the whole-person care we’ve always provided. The questions our patients have been asking all along “Who am I now? What matters? How do I face this?” may finally have a new kind of answer. We should be part of delivering it.
If you’re interested in psilocybin-assisted therapy and would like to connect to talk more about it, please reach out to me at lindseynelsonpsyd@gmail.com.
